Bionano Genomics Inc

Bionano Genomics Inc

BNGO - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$13.54M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Bionano Genomics IncBionano Genomics Inc-0.3--102%0.60.2
$1.11

Current Fair Value

4.4% downside

Overvalued by 4.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$13.54 Million
Enterprise Value$17.66 Million
Earnings per Share$-4.85
Beta1.66
Outstanding Shares11,546,000

Return

Return on Equity-101.76%ROE
Return on Assets-67.58%
Return on Invested Capital-110.10%

Valuation & Multiples

P/E Ratio-0.31P/E Ratio
PEG-3.74PEG
Price to Sales0.58Price to Sales
Price to Book Ratio0.58Price to Book Ratio
Enterprise Value to Revenue0.59
Enterprise Value to EBIT-0.43
Enterprise Value to Net Income-1
Total Debt to Enterprise0.44
Debt to Equity0.25Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 29, 2026
EPS Estimate
$-0.45
Consensus analyst estimate
Revenue Estimate
$8.44 M
Consensus analyst estimate

Next Earnings Call

Expected Date
November 10, 2026
EPS Estimate
$-0.45
Consensus analyst estimate
Revenue Estimate
$8.44 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %6.14%▼ 1.79%
Total Invested$801,579▼ 21.27%
Investors Holding33▲ 2.00%

About Bionano Genomics Inc

147 employees
CEO: R. Erik Holmlin

Bionano Genomics Insider Information FAQ

Stockcircle tracks 2 top investors with a current 13F position in Bionano Genomics. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 2 open-market insider purchases for Bionano Genomics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.